- Home
- Equipment
- usa massachusetts
- innate immunity
Show results for
Refine by
Innate Immunity Equipment Supplied In Usa Massachusetts
6 equipment items found
Manufactured by:Adiso Therapeutics based inConcord, MASSACHUSETTS (USA)
ADS032 is a novel small molecule inhibitor that locally blocks two types of inflammasomes simultaneously, NLRP1 and NLRP3 – the innate immune system’s receptors and first line sensors of pathogens and other danger signals. Chronic activation of NLRP1 and NLPR3 is directly implicated in a wide range of inflammation-triggered conditions across ...
Manufactured by:Mersana Therapeutics based inCambridge, MASSACHUSETTS (USA)
Immunosynthen is our novel immunostimulatory ADC platform designed to take ADCs beyond traditional cytotoxic drugs to targeted stimulation of the innate immune system. Through the safe and efficient delivery of a novel immunomodulatory STING agonist, ADCs created with our Immunosynthen platform have the potential to address the challenges of efficacy, delivery ...
by:Myeloid Therapeutics based inCambridge, MASSACHUSETTS (USA)
Myeloid is focused on advancing its ATAK CAR monocytes, which are myeloid cells with innate immune receptor-inspired CARs to recognize and kill cancer. Additionally, Myeloid has streamlined manufacturing for its ATAK cell therapy candidates through a rapid, single-day cell process. This method provides significant advantages to the patient, contract development, ...
Manufactured by:Vedanta Biosciences, Inc based inCambridge, MASSACHUSETTS (USA)
From Ruslan Medzhitov's discovery of toll-like receptors (TLRs) as the key immune system receptors that detect infection, which spawned the field of innate immunity, to Dan Littman's efforts to identify and clone CD4 and CD8, molecules on the surface of T cells that are crucial to immune recognition and response, Vedanta's ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
Dubermatinib (TP-0903) is an investigational inhibitor of AXL receptor tyrosine kinase (RTK), a protein known to be involved in acquiring resistance to chemotherapeutics, immune evasion, and developing metastatic capacity in cancer ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
DSP-0509 is an investigational Toll-like receptor (TLR) 7 agonist, which is hypothesized to induce cytokine production, activate cytotoxic T lymphocytes, and sustain immune-mediated antitumor ...